Royalty Pharma plc (NASDAQ:RPRX) Holdings Raised by Bryn Mawr Capital Management LLC

Bryn Mawr Capital Management LLC boosted its stake in Royalty Pharma plc (NASDAQ:RPRX) by 564.3% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 56,464 shares of the biopharmaceutical company’s stock after buying an additional 47,964 shares during the period. Bryn Mawr Capital Management LLC’s holdings in Royalty Pharma were worth $1,440,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors also recently made changes to their positions in the stock. Keene & Associates Inc. boosted its holdings in shares of Royalty Pharma by 1.9% in the fourth quarter. Keene & Associates Inc. now owns 19,420 shares of the biopharmaceutical company’s stock valued at $495,000 after acquiring an additional 370 shares in the last quarter. Financial Perspectives Inc bought a new position in Royalty Pharma during the 4th quarter valued at $55,000. D.A. Davidson & CO. boosted its stake in Royalty Pharma by 4.7% during the 4th quarter. D.A. Davidson & CO. now owns 48,146 shares of the biopharmaceutical company’s stock valued at $1,228,000 after purchasing an additional 2,181 shares in the last quarter. Truist Financial Corp acquired a new position in shares of Royalty Pharma during the 4th quarter valued at $371,000. Finally, CIBC Asset Management Inc raised its stake in shares of Royalty Pharma by 4.1% in the 4th quarter. CIBC Asset Management Inc now owns 26,119 shares of the biopharmaceutical company’s stock worth $666,000 after buying an additional 1,028 shares in the last quarter. 54.35% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

Several research analysts recently weighed in on the company. Citigroup decreased their target price on Royalty Pharma from $60.00 to $40.00 and set a “buy” rating for the company in a research note on Friday, October 25th. TD Cowen raised shares of Royalty Pharma to a “strong-buy” rating in a research note on Tuesday, December 24th. Finally, StockNews.com upgraded shares of Royalty Pharma from a “hold” rating to a “buy” rating in a report on Tuesday, November 5th. One analyst has rated the stock with a hold rating, five have given a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus target price of $41.60.

Royalty Pharma Price Performance

NASDAQ RPRX opened at $33.33 on Friday. The company has a current ratio of 1.44, a quick ratio of 1.44 and a debt-to-equity ratio of 0.64. Royalty Pharma plc has a 1 year low of $24.05 and a 1 year high of $33.69. The company has a market cap of $19.64 billion, a PE ratio of 22.99, a PEG ratio of 2.27 and a beta of 0.49. The stock’s 50-day moving average price is $29.01 and its two-hundred day moving average price is $27.89.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings results on Tuesday, February 11th. The biopharmaceutical company reported $1.15 EPS for the quarter, beating the consensus estimate of $0.99 by $0.16. Royalty Pharma had a net margin of 37.94% and a return on equity of 24.40%. On average, analysts predict that Royalty Pharma plc will post 4.49 EPS for the current year.

Royalty Pharma Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Monday, March 10th. Shareholders of record on Friday, February 21st will be paid a $0.22 dividend. The ex-dividend date is Friday, February 21st. This is a boost from Royalty Pharma’s previous quarterly dividend of $0.21. This represents a $0.88 dividend on an annualized basis and a yield of 2.64%. Royalty Pharma’s payout ratio is 60.69%.

Royalty Pharma Company Profile

Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. It is also involved in the identification, evaluation, and acquisition of royalties on various biopharmaceutical therapies. In addition, the company collaborates with innovators from academic institutions, research hospitals and not-for-profits, small and mid-cap biotechnology companies, and pharmaceutical companies.